NYMXF Alzheimer's treatment! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NYMXF Alzheimer's treatment!

NYMXF 0.106

0.0%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jean-Robert Grenier who wrote (76)	3/20/1998 10:34:00 AM
From: Ian@SI	Read Replies (2) of 132

Story on NYMXF in today's WallStreet Journal. interactive.wsj.com Need to be an Interactive WSJ subscriber to access. In respect of their copyright I have not cut and paste the whole story. However, there is a statement that they've published a story in the March edition of Journal of Alzheimers... ... In a news release Monday, Nymox said its research team "has discovered a new human brain entity called the 'spheron,' " that "satisfies 20 criteria of validity as a causal entity for Alzheimer's disease." Spherons are present in every person's brain by the age of one year and eventually grow so big that they can burst and turn into the "senile amyloid plaques" of Alzheimer's disease, according to the researchers. The research results appear in the March issue of the Journal of Alzheimer's Disease, a new publication. ... Paul Coleman, director of the Alzheimer's Disease Center at the University of Rochester Medical Center in Rochester, N.Y., termed the researchers' conclusion a "huge and unwarranted" leap from the evidence presented in the study. Other scientists said that they found the spheron theory intriguing, but that much follow-up research is required to determine if the theory holds up. ... The fact that the March edition is the very first issue of the Journal of Alzheimer's Disease, and that the publication received funding from Nymox, raised eyebrows among scientists. Neither of those facts was mentioned in Nymox's press release Monday. ... An interesting story worth being read in entirety if you're interested in this company... Ian.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next